Update on Retinal Drug Toxicities
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021..
PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities.
RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixertinib, and FGFR inhibitors. Additionally, as previously believed-to-be well-tolerated medications, such as pentosan sulfate sodium, anti-retroviral therapies, and certain intraoperative ocular medications, are used more frequently or for longer periods of time, associated toxic retinopathies and inflammatory reactions have been reported. Finally, advances in ocular imaging have revealed novel findings in hydroxychloroquine and tamoxifen maculopathies.
SUMMARY: Discovery of new medications, increased frequency of use, and longer-term use have led to increased reports of retinal toxicities. Advances in retinal imaging have allowed for earlier detection of subclinical changes associated with these medications, which may help prevent progression of disease. However, more research is needed to determine the point at which vision loss becomes irreversible. Risks and benefits must be assessed prior to discontinuation of the offending, but potentially lifesaving, therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Current ophthalmology reports - 9(2021), 4 vom: 20., Seite 168-177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hsu, S Tammy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug-induced maculopathy |
|---|
| Anmerkungen: |
Date Revised 01.05.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40135-021-00277-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334926246 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334926246 | ||
| 003 | DE-627 | ||
| 005 | 20231225224734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40135-021-00277-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM334926246 | ||
| 035 | |a (NLM)34956737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hsu, S Tammy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update on Retinal Drug Toxicities |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021. | ||
| 520 | |a PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities | ||
| 520 | |a RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixertinib, and FGFR inhibitors. Additionally, as previously believed-to-be well-tolerated medications, such as pentosan sulfate sodium, anti-retroviral therapies, and certain intraoperative ocular medications, are used more frequently or for longer periods of time, associated toxic retinopathies and inflammatory reactions have been reported. Finally, advances in ocular imaging have revealed novel findings in hydroxychloroquine and tamoxifen maculopathies | ||
| 520 | |a SUMMARY: Discovery of new medications, increased frequency of use, and longer-term use have led to increased reports of retinal toxicities. Advances in retinal imaging have allowed for earlier detection of subclinical changes associated with these medications, which may help prevent progression of disease. However, more research is needed to determine the point at which vision loss becomes irreversible. Risks and benefits must be assessed prior to discontinuation of the offending, but potentially lifesaving, therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug-induced maculopathy | |
| 650 | 4 | |a Drug-induced retinopathy | |
| 650 | 4 | |a Hemorrhagic occlusive retinal vasculitis, Brolucizumab, Pentosan sulfate | |
| 650 | 4 | |a Retinal toxicity | |
| 650 | 4 | |a Toxic retinopathy | |
| 700 | 1 | |a Ponugoti, Arathi |e verfasserin |4 aut | |
| 700 | 1 | |a Deaner, Jordan D |e verfasserin |4 aut | |
| 700 | 1 | |a Vajzovic, Lejla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current ophthalmology reports |d 2013 |g 9(2021), 4 vom: 20., Seite 168-177 |w (DE-627)NLM227815548 |x 2167-4868 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:4 |g day:20 |g pages:168-177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40135-021-00277-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 4 |b 20 |h 168-177 | ||